BiotechTube
PeptiDream

PeptiDream

4587.T
Tokyo, Japan· Est.

PeptiDream is a leader in peptide drug discovery, utilizing its innovative PDPS technology to generate diverse, non-standard peptide libraries for identifying drug candidates against 'undruggable' targets. The company has established a highly successful business model based on research collaborations and licensing agreements with global pharmaceutical giants, generating significant non-dilutive funding. Its internal and partnered pipeline spans multiple therapeutic areas, with several candidates in clinical development. PeptiDream's strategy focuses on expanding its platform's reach and advancing key proprietary assets toward commercialization.

peptidream.com

4587.T · Stock Price

JPY 1,182-951 (-44.59%)
Market Cap: $962.7M

Historical price data

AI Company Overview

PeptiDream is a leader in peptide drug discovery, utilizing its innovative PDPS technology to generate diverse, non-standard peptide libraries for identifying drug candidates against 'undruggable' targets. The company has established a highly successful business model based on research collaborations and licensing agreements with global pharmaceutical giants, generating significant non-dilutive funding. Its internal and partnered pipeline spans multiple therapeutic areas, with several candidates in clinical development. PeptiDream's strategy focuses on expanding its platform's reach and advancing key proprietary assets toward commercialization.

OncologyImmunologyInfectious DiseasesOphthalmologyCNS

Technology Platform

Proprietary Peptide Discovery Platform System (PDPS) utilizing Flexizyme-enabled non-standard amino acid incorporation and mRNA display for the rapid discovery and optimization of macrocyclic/constrained peptides against challenging drug targets.

Funding History

2
Total raised:$280M
PIPE$200M
IPO$80M

Opportunities

Significant growth opportunities exist in advancing proprietary immuno-oncology assets like PD-1/IL-2 to later-stage trials and potential approval.
Further expansion of the platform into new modalities (e.g., peptide-drug conjugates, radioligand therapies) and therapeutic areas can drive new partnership revenue.
The company is well-positioned to capitalize on the growing industry demand for novel modalities to drug challenging targets.

Risk Factors

Key risks include clinical failure of lead proprietary programs, technological disruption of its core platform, over-reliance on partnership milestones for revenue, and intellectual property challenges.
The shift towards internal development also increases operational and financial risk.

Competitive Landscape

PeptiDream competes with other peptide-focused biotechs like Bicycle Therapeutics and internal pharma efforts. Its primary differentiation is the unique chemical diversity and integrated speed of its PDPS platform, validated by an unparalleled network of partnerships with top-tier pharmaceutical companies, creating a significant competitive moat.

More companies in Proteomics & Protein Engineering →More companies in Japan →